首页> Investigational new drugs> A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study.

导出 OA

翻译打印收藏纠错

第一作者： Manish K,Thakur

第一单位： Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.

作者： Manish K,Thakur ^[1] ; Lance K,Heilbrun ^[1] ; Shijie,Sheng ^[1] ; Mark,Stein ^[2] ; Glenn,Liu ^[3] ; Emmanuel S,Antonarakis ^[4] ; Ulka,Vaishampayan ^[1] ; Sijana H,Dzinic ^[1] ; Xiaohua,Li ^[1] ; Stacy,Freeman ^[1] ; Daryn,Smith ^[1] ; Elisabeth I,Heath ^[5]

作者单位： Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. ^[1] Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. ^[2] University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA. ^[3] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. ^[4] Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. heathe@karmanos.org. ^[5]

关键词 Ganetespib Heat shock protein Prostate cancer